Virios Therapeutics, Inc. is a biotechnology firm in its development phase, dedicated to pioneering antiviral treatments for conditions that arise from an unusual immune response triggered by viral infections. Its primary investigational compound, IMC-1, is a precisely formulated blend of famciclovir and celecoxib, currently being developed to address fibromyalgia. Additionally, the company is advancing IMC-2, a therapeutic combination of valacyclovir and celecoxib, aimed at mitigating the various long COVID symptoms, including ongoing fatigue, sleep disturbances, cognitive challenges, pain, autonomic dysfunction, and anxiety. Founded in 2012, the organization was initially known as Virios Therapeutics, LLC, before officially changing its name to Virios Therapeutics, Inc. in December 2020. The company's headquarters are located in Alpharetta, Georgia.
